| Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors (NCT04383210) | Elevation Oncology | 2020-09-29 |
| A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers (NCT04260802) | Ocellaris Pharma, Inc. | 2020-09-24 |
| Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC (NCT04140526) | OncoC4, Inc. | 2020-09-16 |
| PF-07104091 as a Single Agent and in Combination Therapy (NCT04553133) | Pfizer | 2020-09-16 |
| Intensive Intraperitoneal Therapy in Advanced Ovarian Cancer (NCT04282356) | Institut du Cancer de Montpellier - Val d'Aurelle | 2020-09-15 |
| PITCHER (Peritoneal Carcinomatosis Heterogeneity) (NCT04714957) | Hospices Civils de Lyon | 2020-09-01 |
| Tumor Grade Determines PD-1/PDL-1 Expression (NCT04528940) | RWJ Barnabas Health at Jersey City Medical Center | 2020-08-25 |
| Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery (NCT04498117) | CanariaBio Inc. | 2020-08-25 |
| Niraparib and Neratinib in Advanced Solid Tumors With Expansion Cohort in Advanced Ovarian Cancer (NCT04502602) | Virginia Commonwealth University | 2020-08-24 |
| Aspirin for Prevention of Venous Thromboembolism Among Ovarian Cancer Patients Receiving Neoadjuvant Chemotherapy (NCT04352439) | Duke University | 2020-08-08 |
| A Study to Evaluate the Effectiveness and Tolerability of a Second Maintenance Treatment in Participants With Ovarian Cancer, Who Have Previously Received Polyadenosine 5'Diphosphoribose [Poly (ADP Ribose)] Polymerase Inhibitor (PARPi) Treatment. (NCT04239014) | AstraZeneca | 2020-08-07 |
| Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib (NCT04421963) | AstraZeneca | 2020-08-04 |
| A Study of Niraparib in Patients With Relapsed Ovarian Cancer (NCT04392102) | Zai Lab (Shanghai) Co., Ltd. | 2020-08-04 |
| A Study of the PD-L1xCD27 Bispecific Antibody CDX-527 in Patients With Advanced Malignancies (NCT04440943) | Celldex Therapeutics | 2020-08-04 |
| A Randomized Prospective Trail of HIPEC in Recurrent Ovarian Cancer Patients With HRR Mutation (NCT04473339) | CAI Hongbing | 2020-08-01 |
| Radiomics and Machine Learning in the Diagnosis of Ovarian Masses (NCT06342934) | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | 2020-07-22 |
| A Study of Serum Folate Levels in Patients Treated With Olaparib (NCT04024254) | Rush University Medical Center | 2020-07-21 |
| Gyn Onc Prehab Study (NCT04298827) | St. Louis University | 2020-07-21 |
| Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S (NCT04430842) | Quadriga Biosciences, Inc. | 2020-07-20 |
| Journey Ahead: Enhancing Coping and Communication for Women Diagnosed With Gynecological Cancer (NCT05220033) | Rutgers, The State University of New Jersey | 2020-07-14 |
| A Phase I Trial of CCT303-406 in Patients With Relapsed or Refractory HER2 Positive Solid Tumors (NCT04511871) | Shanghai PerHum Therapeutics Co., Ltd. | 2020-07-09 |
| Niraparib as Maintenance Treatment in Platinum Responsive Ovarian Cancer Patients: a Real Life Study (NCT04617470) | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | 2020-07-08 |
| Immuno Monitoring in Patient With Epithelial Ovarian Cancer Eligible to PARP Inhibitors (NCT04675320) | Centre Georges Francois Leclerc | 2020-07-07 |
| Family History Study on Cancer Risk (NCT04145388) | Kaiser Permanente | 2020-07-01 |
| Delayed Initiation of Olaparib Maintenance Therapy in Platinum Sensitive Recurrent Ovarian Cancer (NCT04377087) | Sarah E Taylor | 2020-06-29 |
| Arsenic Trioxide in Recurrent and Metastatic Ovarian Cancer and Endometrial Cancer With P53 Mutation (NCT04489706) | Ruijin Hospital | 2020-06-28 |
| Minimally Invasive Robotic Surgery, Role in Optimal Debulking Ovarian Cancer, Recovery & Survival (NCT04402333) | Royal Surrey County Hospital NHS Foundation Trust | 2020-06-26 |
| Zafirlukast in Treatment of Marker Relapsed Ovarian Cancer (NCT04339140) | Beth Israel Deaconess Medical Center | 2020-06-24 |
| Using Advanced Imaging Studies to Develop a Profile of High-grade Serous Ovarian Cancer (NCT04454450) | Memorial Sloan Kettering Cancer Center | 2020-06-22 |
| NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors (NCT04332653) | NeoImmuneTech | 2020-06-10 |
| Docetaxel Ethanol-induced Symptoms; The Incidence and Risk Forecating Factor (NCT04545632) | Boryung Pharmaceutical Co., Ltd | 2020-06-10 |
| A Safety and Tolerability Study of NC410 in Subjects With Advanced or Metastatic Solid Tumors (NCT04408599) | NextCure, Inc. | 2020-06-10 |
| Rucaparib MAintenance After Bevacizumab Maintenance Following Carboplatin Based First Line Chemotherapy in Ovarian Cancer Patients (NCT04227522) | North Eastern German Society of Gynaecological Oncology | 2020-06-08 |
| Study of Radspherin® in Recurrent Ovarian Cancer Subjects With Peritoneal Carcinomatosis (NCT03732768) | Oncoinvent Solutions AS | 2020-06-08 |
| A Study of Fluzoparib±Apatinib Versus Placebo Maintenance Treatment in Patients With Advanced Ovarian Cancer Following Response on First-Line Platinum-Based Chemotherapy (NCT04229615) | Jiangsu HengRui Medicine Co., Ltd. | 2020-06-02 |
| HIPEC in the Treatment of Stage IIc-IV Epithelial Ovarian Cancer After CRS (HIPECOC) (NCT04280185) | Second Affiliated Hospital, Zhejiang University, School of Medicine | 2020-06-01 |
| Feasibility of Frailty Assessment and Implementation of Interventions in Women Over 70 With Epithelial Ovarian Cancer (NCT04300699) | Royal Marsden NHS Foundation Trust | 2020-06-01 |
| A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer (NCT04254107) | Seagen Inc. | 2020-05-29 |
| Effect of Hemp-CBD on Patients With CIPN (NCT04398446) | Main Line Health | 2020-05-27 |
| Prospective Multicentre Phase-IV Clinical Trial of Olaparib in Indian Patients With Ovarian and Metastatic Breast Cancer (NCT04330040) | AstraZeneca | 2020-05-25 |
| Efficacy and Safety of Niraparib Combined With Oral Etoposide in Platinum Resistant/Refractory Recurrent Ovarian Cancer (NCT04217798) | Peking Union Medical College Hospital | 2020-05-21 |
| First-in-Human Study of XMT-1592 in Patients With Ovarian Cancer and NSCLC Likely to Express NaPi2b (NCT04396340) | Mersana Therapeutics | 2020-05-11 |
| Niraparib Maintenance in Patients With Advanced Ovarian Cancer at Neoadjuvant Setting (NCT04284852) | The University of Hong Kong | 2020-05-01 |
| Apatinib and Etoposide Capsule Versus Apatinib in Patients With Platinum Resistant Ovarian Cancer (NCT04383977) | Jiangsu HengRui Medicine Co., Ltd. | 2020-05-01 |
| Factors Affecting the Prognosis of Early Ovarian Cancer (NCT04414683) | Far Eastern Memorial Hospital | 2020-04-13 |
| Clinical Characters of the Diagnosis and Treatment of Gynecological Malignant Tumors in China : A Real World Study (NCT04214964) | Tongji Hospital | 2020-04-11 |
| COM902 (A TIGIT Inhibitor) in Subjects With Advanced Malignancies (NCT04354246) | Compugen Ltd | 2020-03-31 |
| αPD1-MSLN-CAR T Cells for the Treatment of MSLN-positive Advanced Solid Tumors (NCT04503980) | Shanghai Cell Therapy Group Co.,Ltd | 2020-03-26 |
| Feasibility of a New Technology for Isolating Circulating Tumour Cells (NCT03979339) | Centre Oscar Lambret | 2020-03-11 |
| Palbociclib Plus Letrozole Treatment After Progression to Second Line Chemotherapy for Women With ER/PR-positive Ovarian Cancer (NCT03936270) | Latin American Cooperative Oncology Group | 2020-03-05 |
| TUBectomy With Delayed Oophorectomy in High Risk Women to Assess the Safety of Prevention (NCT04294927) | University Medical Center Nijmegen | 2020-03-01 |
| ATR Inhibitor Elimusertib (BAY1895344) Plus Niraparib Phase 1b Study in Advanced Solid Tumors and Ovarian Cancer (NCT04267939) | Bayer | 2020-02-26 |
| Effects of Centering Pre-operative Counseling on Patient Reported Anxiety (NCT04068675) | Northwestern University | 2020-02-24 |
| Determination of the Feasibility of Tumoural Somatic Mutations Detection in Blood of Patients With Ovarian Cancer (NCT03881683) | Institut de Cancérologie de Lorraine | 2020-02-21 |
| Feasibility of a Clinical Trial Comparing the Use of Cetirizine to Replace Diphenhydramine in the Prevention of Reactions Related to Paclitaxel (NCT04237090) | Ciusss de L'Est de l'Île de Montréal | 2020-02-14 |
| Exemestane in Hormone Receptor Positive High Grade Ovarian Cancer (NCT04460807) | Ente Ospedaliero Ospedali Galliera | 2020-02-13 |
| A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies (NCT04244552) | Atreca, Inc. | 2020-02-11 |
| Effect of PARP Inhibitors on Glomerular Filtration Rate (NCT04367467) | University of Pennsylvania | 2020-02-03 |
| Multi-Centre Observational Study of Maintenance Niraparib in Treatment of Ovarian CanceR (NCT04295577) | Royal Marsden NHS Foundation Trust | 2020-02-03 |
| Deciphering Mechanisms Underlying Cancer Immunogenicity (NCT03958240) | Institut Claudius Regaud | 2020-01-17 |
| Validation of the Russian and Kazakh Versions of the Beck Depression Inventory and Beck Anxiety Inventory (NCT04630327) | Kazakh Medical University of Continuing Education | 2020-01-13 |
| Appropriate Dosing to Optimise Personalised Cancer Treatments (NCT04154163) | University of Dundee | 2020-01-10 |
| Implementing Enhanced Recovery After Surgery (ERAS) Pathways In Major Gynecologic Oncology Operations In Greece (NCT04696276) | University of West Attica | 2020-01-06 |
| Diagnosing Ovarian Cysts - the DOC Study (NCT04188652) | Rigshospitalet, Denmark | 2020-01-01 |
| Imaging Study in Advanced Ovarian Cancer (NCT03808792) | Charles University, Czech Republic | 2020-01-01 |
| Primary Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy (HIPEC) (NCT03772028) | The Netherlands Cancer Institute | 2020-01-01 |
| High Dose Inorganic Selenium for Preventing Chemotherapy Induced Peripheral Neuropathy (NCT04201561) | Seoul National University Hospital | 2019-12-24 |
| A Study of IMP4297 as Maintenance Treatment Following First-line Chemotherapy in Patients With Advanced Ovarian Cancer (NCT04169997) | Impact Therapeutics, Inc. | 2019-12-24 |
| OPTimizing Treatment Focused Genetic Testing IN Cancer (NCT04066361) | Dana-Farber Cancer Institute | 2019-12-19 |
| Prehabilitation Care for Women With Advanced Ovarian Cancer Receiving Neoadjuvant Chemotherapy (NCT04204811) | Memorial Sloan Kettering Cancer Center | 2019-12-16 |
| Bosutinib in Combination With Pemetrexed in Patients With Selected Metastatic Solid Tumors (NCT03023319) | Nagla Abdel Karim | 2019-12-10 |
| Role of Laparoscopy in Assessing Resectability of Ovarian Cancer (NCT05564234) | Zagazig University | 2019-12-09 |
| Feasibility of Opportunistic Salpingectomy During Non-Gynecologic Surgery (NCT04176484) | University of Virginia | 2019-12-01 |
| Ovarian Cancer Treatment With a Liposome Formulated mRNA Vaccine in Combination With (Neo-)Adjuvant Chemotherapy (NCT04163094) | University Medical Center Groningen | 2019-11-25 |
| Focused Ultrasound Ablation and PD-1 Antibody Blockade in Advanced Solid Tumors (NCT04116320) | Craig L Slingluff, Jr | 2019-11-21 |
| The Lifestyle and Empowerment Techniques in Survivorship of Gynecologic Oncology Study (NCT04122235) | Sorlandet Hospital HF | 2019-11-18 |
| Efficacy of Plasmid Elenagen in Combination With Gemcitabine in Patients With Platinum-resistant Ovarian Cancer (NCT05979298) | CureLab Oncology | 2019-11-15 |
| Newton Study (NEW Dosing MainTenance Therapy Ovarian CaNcer) (NCT03891576) | Mario Negri Institute for Pharmacological Research | 2019-11-13 |
| Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression (NCT04180371) | BicycleTx Limited | 2019-11-07 |
| Real World Data Analysis of PARP Inhibitors Use in Patients With Ovarian Cancer (NCT04724031) | Hellenic Cooperative Oncology Group | 2019-11-01 |
| Study of IMP4297 in Patients With BRCA1/2 Mutation Ovarian Cancer (NCT04089189) | Impact Therapeutics, Inc. | 2019-10-28 |
| The Role of Cytomegalovirus and Inflammation on Patient Symptoms and Outcomes in Ovarian Cancer (NCT03921658) | University of Minnesota | 2019-10-22 |
| Tolerance of Intraperitoneal (IP) Nivolumab After Extensive Debulking Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Ovarian Carcinoma (NCT03959761) | Hospices Civils de Lyon | 2019-10-17 |
| Study of NGM120 in Subjects With Advanced Solid Tumors, Pancreatic Cancer, and Prostate Cancer Using Combination Therapy (NCT04068896) | NGM Biopharmaceuticals, Inc | 2019-10-16 |
| Optimal Timing of BR55 CEUS of the Ovaries (NCT04248153) | Bracco Diagnostics, Inc | 2019-10-14 |
| Characterization of Biophysical Stromal Properties in Human Cancer: Towards Personalized Computational Oncology (NCT04512209) | University Hospital, Ghent | 2019-10-11 |
| Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumor, Including a Cohort Expansion in Esophageal Cancer. (NCT03983954) | NeoTX Therapeutics Ltd. | 2019-10-10 |
| A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors (NCT03997968) | Cyteir Therapeutics, Inc. | 2019-10-09 |
| Acupressure for Fatigue in Ovarian Cancer Survivors (NCT03763838) | University of Michigan Rogel Cancer Center | 2019-10-07 |
| Study to Evaluate the Safety of Nanoxel M Inj. (NCT04066335) | Samyang Biopharmaceuticals Corporation | 2019-09-18 |
| Detection of Circulating Tumor DNA Through Liquid Biopsies in Ovarian Cancer Patients and Evaluation of Prognostic and Predictive Values of Circulating Tumor DNA Assay. (NCT05504174) | Yonsei University | 2019-09-10 |
| Efficacy of Platinum-based Chemotherapy in Platinum-resistant Ovarian Cancer) (EPITOC) (NCT04055038) | Blokhin's Russian Cancer Research Center | 2019-09-01 |
| Apatinib With Albumin-bound Paclitaxel in Patients With Platinum-resistant Recurrent Ovarian Cancer (NCT03942068) | Henan Cancer Hospital | 2019-09-01 |
| ADP-A2M4CD8 as Monotherapy or in Combination With Either Nivolumab or Pembrolizumab in HLA-A2+ Subjects With MAGE-A4 Positive Tumors (SURPASS) (NCT04044859) | USWM CT, LLC | 2019-08-20 |
| Apatinib and Etoposide Capsule Versus Weekly Paclitaxel in Patients With Platinum Resistant Ovarian Cancer (NCT04000295) | Jiangsu HengRui Medicine Co., Ltd. | 2019-08-16 |
| The Fourth Generation CART-cell Therapy for Refractory-Relapsed Ovarian Cancer (NCT03814447) | Shanghai 6th People's Hospital | 2019-08-16 |
| A Study to Evaluate ONM-100, an Intraoperative Fluorescence Imaging Agent for the Detection of Cancer (NCT03735680) | OncoNano Medicine, Inc. | 2019-08-09 |
| ICG-Enabled Mapping of Ovarian Sentinel Lymph Nodes: A Feasibility Study (NCT04051502) | Memorial Sloan Kettering Cancer Center | 2019-08-05 |
| Pamiparib in Fusion Positive, Reversion Negative High Grade Serous Ovarian Cancer or Carcinosarcoma With BRCA1/2 Gene Mutations If Progression on Substrate Poly ADP Ribose Polymerase Inhibitbor (PARPI) or Chemotherapy (NCT03933761) | Australia New Zealand Gynaecological Oncology Group | 2019-07-29 |
| PARP Inhibition During Pre-surgical Window in Breast/Ovary Cancer (NCT04041128) | University of Texas Southwestern Medical Center | 2019-07-23 |